Comparison of Adverse Event (AE) Management Costs of Chimeric Antigen Receptor T-Cell (CAR T) Therapies in 4L+ Relapsed And/Or Refractory Multiple Myeloma (RRMM)

anitocabtagene autoleucel (CART-ddBCMA) - Gilead, Kite Pharma

Carvykti (ciltacabtagene autoleucel) - J&J

Abecma (idecabtagene vicleucel) - BMS

Rahul Banerjee1; Lekha Mikkilineni2; Avik Ray3; Jie Ting4; Ken Hasegawa5; Samuel Hong5; William Ngantung6; Matia Saeedian6; Matthew J. Frigault7

Sep 11, 2026